1. Access to NOAC Therapy:

3. Program Goals

4. Appropriate Use of Anticoagulants in the Setting of NVAF

5. Drug Initiation of Dabigatran or Warfarin in Patients With AF (2014)

6. Influence of Anticoagulant Dosing Orbit AF II Registry

7. Anticoagulant Adherence

8. OAC is the Most Effective Medicine for Stroke Prevention

9. Bleeding Risk With NOACs

10. Higher Copays Associated With Treatment Abandonment or Delay

11. Burden and Barriers to Adherence

12. ARISTOTLE: Apixaban vs Warfarin in AF

13. Care Delivery: Prevention of Thrombosis

14. Meds-To-Beds Program

15. General Approach to NOAC Use in Treatment of AF

16. Patient Assistance Programs

17. Methods to Improve Patient Adherence and Empower Patients with AF

18. Applications for the Clinician

19. Non-Medical Switching: A Prescription for Disaster

20. NATF Patient Support Group

21. Tools to Help Patients Understand the Importance of Treatment in AF

22. Guidelines on NOAC Use in AF

23. The Impact of Educational Intervention (IMPACT-AF)

24. AVERROES Trial: Apixaban vs Aspirin

25. Warfarin vs Aspirin for Stroke Prevention in AF

26. Events Leading to Discontinuation of OAC

27. Concluding Remarks

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)

31. Abbreviations (cont)